Judge OKs Generic for Bristol-Myers’ BuSpar
Mylan Laboratories Inc. said a federal judge ruled that the generic-drug maker doesn’t infringe rival Bristol-Myers Squibb Co.’s patent for the anti-anxiety drug, BuSpar.
U.S. District Judge John Koeltl also denied Bristol-Myers’ motion to dismiss Mylan’s antitrust claims, the company said.
Twenty-nine state attorneys, Mylan and Watson Pharmaceuticals Inc. sued Bristol-Myers, accusing the largest cancer drug maker of thwarting competition by using a compound related to BuSpar to delay generic competition.
In turn, Bristol-Myers sued Mylan and Watson for patent infringement.
Officials at New York-based Bristol-Myers, which had $709 million in BuSpar sales in 2002, could not be reached for comment after hours.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
